Newsletter

Today's play provided for solid gains as it jumped from $0.0091 to $0.0120 (32% gain), and now I want more.

I came across another opportunity that I think has significant gain potential.

Breathe eCig Corp (BVAP) is a low priced play with plenty of upside and a thin level 2.

BVAP has pulled back from its recent trading range but has found a solid base where it has been consolidating for several days now.

It recently spiked to almost $0.09, and for the past six months has spent most of its time trading above $0.07.

This pullback to $0.035-0.038 could be a great dip buying opportunity in BVAP.

Encouragingly, we see a lot of support at various prices in level 2 which could give this a platform for a move higher.

And best of all, nice liquidity has started to come in to BVAP recently, which gives us an opportunity to enter & exit with relative ease.

In a nutshell, BVAP has been trading in a wide range over the past several months. It has pulled back to support / bottom of range.

Buying at the bottom end of the range could represent a very good risk v reward trade as we look to see it move back towards the higher end of the trading range.





About BVAP

BVAP has created a new groundbreaking e-cigarette to compete in the multi-billion dollar electronic cigarette industry.

BVAP's mission is to provide the highest quality electronic cigarette products, and e-cig experience, to the market. Further, they aim to develop the e-cig into a beneficial use with higher quality standards and safety improvements in the device to prevent misuse by adults or accidental usage by children.

Equally, BVAP’s goal is to maintain the highest possible environmental standards, educate, as well as, funding and supporting youth programs. Vaporization has many possibilities to benefit, health and safety issues. Breathe will remain true to corporate profit goals, and strong individual values as we participate in the competitive market.

The company has multiple pending patents and trademarks, related to the safety of vaporization. Breathe is revolutionizing the industry, by having founder Josh Kimmel the first Vapor Sommelier ™., handcraft flavors, to a before flavorless industry.


Made in the USA

All of BVAP's consumables are made in the USA. And with their proprietary technology and home grown-hand crafted flavors, BVAP aims to differentiate themselves and become one of the dominant US based e-cigarette providers with a Globally recognized Brand specializing in organic & naturally flavored e-Cigarettes.

 

Staggering Industry Growth

Bonnie Herzog, with Wells Fargo Securities, estimates that eCig sales may rise from $2.0 Billion in 2014 to $10 billion over the next three years

According to Euromonitor, e-cigarettes accounted for approximately $3.5 billion in 2013 global retail sales, w/ approximately 40% of sales generated in the U.S., 30% of sales generated in Europe, & 30% of sales generated in the rest of the world. Euromonitor also projects e-cigarette sales to represent approximately $51 billion, or 4% of the global tobacco & tobacco alternatives market by 2030.

 

 

The Breathe eCig Difference

• Breathe e-Cigs feature Tennessee, USA tobacco-sourced nicotine, handcrafted and perfected by our Founder, an advanced level wine sommelier, producing the best taste of any e-cig in the industry, with lower price point than market leaders.
• Breathe eCigs stands out from the competition by being the first Socially Responsible e-Cigarette, and endorsed by top medical experts in the country.
• Breathe’s e-Cigs possess innovative functionality and consumer safety features, such as child protective devices not found in other brands.
• Multiple pending patents in regards to child protection and the ability to regulate the amount of nicotine or herbal substance, including cannabis , that can be vaporized through vaporization or any class 2 medical device.

LOS ANGELES  and KNOXVILLE, Tenn., March 16, 2015 /PRNewswire/ -- Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, and Breathe eCig Corp. (BVAP) ("Breathe"), a socially responsible e-cigarette company, announced today that the two companies have entered into a license agreement to co-develop and co-commercialize a new cannabidiol (CBD) e-cigarette.  This new product will utilize Breathe's patent pending, proprietary device that dispenses a measured and consistent amount of active ingredient per puff and that also features an optional childproofing device.  Tauriga will be responsible for the active ingredient and will source and qualify the CBD oil and will formulate the contents of the pre-filled cartridges and refill units.  Tauriga and Breathe will share the net profits equally from the CBD e-cigarette product line.

Tauriga Chairman and CEO Dr. Stella M. Sung states, "This agreement represents a true partnership for developing an exciting product line that reflects our shared vision of cannabis as an important and rich source for natural and complementary medicine."

CBD has been associated with many medicinal properties and therapeutic benefits, yet unlike THC, it does not create a psychoactive "high."  Preclinical studies using animal models suggest that CBD has anticonvulsant, anxiolytic/anti-depressant, anti-inflammatory, antiemetic, and anti-oxidant properties.  As such, CBD may have important therapeutic benefits in the treatment of a wide range of conditions, including chronic pain, neurodegenerative diseases, anxiety, nausea, cancer, arthritis, and other health concerns.

Breathe's founder and CEO Josh Kimmel commented, "The CBD e-cigarette product line that we are co-developing with Tauriga is an ideal application of our technology and is absolutely consistent with our goal of reducing secondhand smoke and other dangers associated with conventional combustible cigarettes.  We also have the ability to quickly expand our CBD e-cigarette product line by incorporating Breathe's organic and natural flavors and advanced vapors developed in an FDA-certified factory."

Both Tauriga and Breathe believe there is a large and dynamic market for CBD e-cigarettes, and the companies' new product line will combine attractive and sought after components in two rapidly growing sectors, e-cigarettes and natural wellness.   According to  a March, 2014 equity research report from Wells Fargo Securities, LLC,  the current US retail e-vapor market is an estimated $2.2 billion, and much of the near term growth will be driven by the vapors and tanks (the natural wellness content), even more so than by the devices.

Tauriga's recently launched natural wellness product line currently consists of six products.  Two of these products contain cannabidiol (CBD) oil extracted from non-GMO industrial hemp as their key ingredient: CannaCaviar, the Company's cannabidiol (CBD) soft gels; and TopiCanna, Tauriga's proprietary topical medicinal cannabis cream.  Both TopiCanna and CannaCaviar are designed to provide potential natural wellness and healing properties without psychoactive effects.  In addition to CannaCaviar and TopiCanna, Tauriga has a non-cannabis containing line of natural wellness dietary supplements.  These natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and MendWCan, a highly pure, potent and palatable Omega 3 supplement.

To read in full, visit http://finance.yahoo.com/news/tauriga-sciences-inc-breathe-ecig-110000842.html